Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered ...

As for KT-621, the once-daily oral degrader of STAT6 protein is set to undergo a Phase 1b trial for atopic dermatitis (AD) in Q1, with data expected in Q4 2025. Phase 2b trials for KT-621 in AD ...

A statement from Gilead indicates that the deal is likely to lower its 2025 GAAP and non-GAAP earnings per share by $0.15 to ...

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory ...

STAT6 is a transcription factor essential for IL-4 and IL-13 cytokine signalling, which are validated targets for Th2 mediated inflammatory conditions such as atopic dermatitis. Credit: ...

The potential acquisition comes as J&J seeks to bolster its portfolio. Credit: Skorzewiak/Shutterstock. Johnson & Johnson (J&J) has announced it will acquire Intra-Cellular Therapies, a company ...

N-Power Medicine, a company leading the reinvention of the clinical trial process, today announced the acquisition of Syapse Holdings Inc. ("Syapse"), a pioneer in precision medicine solutions for ...

According to the newly published Global Retail Cash Automation 2025 study from RBR Data Services, a division of research and consulting firm Datos Insights, GLORY (TYO:6457) continues to lead the ...